🔔 Brokerage Recommendation Alert
Religare Broking suggests accumulating HDFC Bank shares in the Rs 1,720-1,810 range, targeting Rs 1,920-2,008 levels in 2025.
HDFC Bank Ltd Analyst Rating
based on 41 analysts
82.93%
Buy
17.07%
Hold
0.00%
Sell
Based on 41 analysts offering long term price targets for HDFC Bank Ltd. An average target of ₹1956.66
Source: S&P Global Market Intelligence
HDFC Bank Ltd Share analysis
HDFC Bank Ltd price forecast by 41 analysts
Upside of8.81%
High
₹2550
Target
₹1956.66
Low
₹1554
HDFC Bank Ltd target price ₹1956.66, a slight upside of 8.81% compared to current price of ₹1798.25. According to 41 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
HDFC Bank Ltd revenue growth forecast
Expected growth rate Q1, FY2026:0
Forecast
Actual
Including amortisation and stock based compensations
HDFC Bank Ltd EPS growth forecast
EPS estimate Q1, FY2026:19.77%
Forecast
Actual
Source: S&P Global Market Intelligence
HDFC Bank Ltd Performance
Day's Low
Day's High
₹1,789.1Day's Price Range₹1,805.9552 Week's Low
52 Week's High
₹1,363.5552-Week Price Range₹1,880
| Returns % | |
| 1 Month Return | + 0.28 % |
| 3 Month Return | + 3.82 % |
| 1 Year Return | + 5.45 % |
| Market Stats | |
| Previous Close | ₹1,790.75 |
| Open | ₹1,794.80 |
| Volume | 36.30L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹13,69,515.42Cr |
HDFC Bank Ltd Key Statistics
| P/E Ratio | 19.76 |
| PEG Ratio | 15.68 |
| Market Cap | ₹13,69,515.42 Cr |
| P/B Ratio | 2.5 |
| EPS | 86.15 |
| Dividend Yield | 1.35 |
| Sector | Banks |
| ROE | 16.88 |
HDFC Bank Ltd Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹13,69,515.42 Cr | 8.05% | NA | ₹64,062 Cr | ₹4,07,994 Cr | |
| BUY | ₹72,603.72 Cr | -7.55% | NA | ₹8,977 Cr | ₹55,143 Cr | |
| BUY | ₹26,012.35 Cr | -13.63% | NA | NA | NA | |
| BUY | ₹9,15,672.20 Cr | 28.08% | NA | ₹44,256 Cr | ₹2,36,037 Cr | |
| BUY | ₹3,33,234.84 Cr | 8.58% | NA | ₹26,386 Cr | ₹1,37,989 Cr |
About HDFC Bank Ltd
HDFC Bank's popular brands include HDFC Bank SmartUp, HDFC Bank InstaBanking, HDFC Bank PayZapp, HDFC Bank EasyEMI, HDFC Bank MoneyBack Credit Card and HDFC Bank Diners Card. The bank also has a range of digital banking services such as HDFC Bank Mobile Banking, HDFC Bank Net Banking, HDFC Bank Phone Banking and HDFC Bank UPI. A notable fact about HDFC Bank is that it was the first Indian bank to launch an IPO in 1995, which was oversubscribed 55 times. Another interesting fact is that HDFC Bank is the largest credit card issuer in India.
The parent company, Housing Development Finance Corporation, is a prominent player in India's housing finance sector. In a significant merger and acquisition (M&A) move, HDFC Ltd. and HDFC Bank announced a merger in 2022, aimed at creating a financial giant by combining their strengths in housing finance and banking. This merger is expected to enhance the bank's product offerings and expand its customer base.
Share Price: ₹1798.25 per share as on 27 Dec, 2024 04:01 PM
Market Capitalisation: ₹13,69,515.42Cr as of today
Revenue: ₹1,21,456.74Cr as on September 2024 (Q3 24)
Net Profit: ₹17,825.91Cr as on September 2024 (Q3 24)
Listing date: 14 Jun, 1995
Chairperson Name: Atanu Chakraborty
| Organisation | HDFC Bank Ltd |
| Headquarters | Mumbai |
| Industry | Banks |
| E-voting on shares | Click here to vote |
Key events for HDFC Bank Ltd
HDFC Bank Shows Recovery Signs Post-Merger - 28 Dec, 2024
HDFC Bank's share fell post-merger but shows recovery signs with improved credit-to-deposit ratio. Analysts recommend accumulating shares, targeting Rs 1,920-2,008.HDFC Bank Faces Credit Growth Challenges - 27 Dec, 2024
HDFC Bank, following its merger with HDFC Ltd, is experiencing slower loan book growth compared to the industry average, impacting overall credit growth in the economy.HDFC Bank Strengthens AI Initiatives Amid Profit Growth - 26 Dec, 2024
HDFC Bank continues to enhance its AI capabilities for better decision-making. The RBI has formed a committee for AI ethics, with HDFC's Anjani Rathor as a member. Additionally, banks report a sixth year of profit growth, reflecting a strong balance sheet performance.HDFC Bank Shows Strong Performance and Growth Plans - 24 Dec, 2024
HDFC Bank demonstrates solid performance with a 5% profit rise in Q2 FY2025 and plans to unlock value through an IPO for HDB Financial Services. The bank also gains market share in credit cards, reflecting positive market sentiment and broker optimism.HDFC Bank Executes Gold Deal, Shares Rise - 23 Dec, 2024
HDFC Bank's shares rose nearly 2% following Emkay Global's positive outlook and target price increase. The bank also executed its first gold forward deal from GIFT City, showcasing its commitment to the bullion market.HDFC Securities Sees Challenges and Opportunities Ahead - 20 Dec, 2024
HDFC Securities predicts a challenging 2025 due to high valuations but highlights stock-picking opportunities in large banks, including HDFC Bank, amid market uncertainties.HDFC Capital Expands into PropTech Sector - 19 Dec, 2024
HDFC Capital has diversified from a private equity fund to launch an affordable real estate technology platform, aiming to enhance efficiency in the PropTech ecosystem.HDFC Bank Faces Challenges Amid Strategic Partnerships - 18 Dec, 2024
HDFC Bank is navigating challenges, including a SEBI warning and market performance issues, while also contributing to startup growth and achieving significant guarantees for loans.HDFC Bank Faces Regulatory Challenges Amid Positive Earnings - 17 Dec, 2024
HDFC Bank's shares faced pressure from SEBI warnings regarding compliance issues, while the bank reported a 5.3% YoY PAT rise and received a BUY rating from StoxBox.HDFC Bank Faces SEBI Scrutiny Over Disclosure Issues - 16 Dec, 2024
HDFC Bank received multiple warnings from SEBI for failing to disclose Arvind Kapil's resignation timely. Despite regulatory scrutiny, the bank reported strong Q2 results and plans to address compliance issues.HDFC Bank Shows Strong Performance and Bullish Indicators - 15 Dec, 2024
HDFC Bank has been outperforming frontline indices, trading above both short and long-term moving averages. The daily RSI indicates a strong bullish trend, with immediate support at 1840-1830 and potential upside targets of 1960 and 2000.HDFC Bank Receives SEBI Warning Letter - 12 Dec, 2024
HDFC Bank was issued an administrative warning by SEBI for non-compliance with various regulations. The bank assured stakeholders that there would be no financial or operational impact.HDFC Bank Secures Major Office Lease in Navi Mumbai - 11 Dec, 2024
HDFC Bank has signed a lease for 416,000 sq ft of office space in Navi Mumbai for 10 years, with an annual rent of Rs 24 crore. The lease includes provisions for car parking and a rental escalation clause.HDFC Bank Expands Operations and Secures Funding - 10 Dec, 2024
HDFC Bank is expanding its operations by leasing significant office space in Navi Mumbai and successfully raised $750 million through overseas bonds, while Bajaj Holdings acquired a small stake in the bank.HDFC Bank Announces MCLR Hike and Strategic Partnerships - 09 Dec, 2024
HDFC Bank has increased its MCLR for short-term loans and announced a partnership with Zaggle, which has positively impacted Zaggle's stock. SEBI also issued a warning regarding unlisted securities trading.HDFC Bank Reports Strong Earnings Growth - 07 Dec, 2024
HDFC Bank announced strong net earnings of INR 168.2 billion for 2QFY25, reflecting an 18% YoY growth. Despite modest loan growth, strong deposit growth supports liquidity and a positive outlook.HDFC Bank Sees Inflows Amid Safe Haven Buying - 06 Dec, 2024
HDFC Bank's stock performance is influenced by safe haven buying, significant foreign inflows from MSCI rebalancing, and a decrease in Cash Reserve Ratio. The bank remains a leading card issuer.HDFC Bank Faces Caution Amid Growth Concerns - 05 Dec, 2024
JPMorgan maintains a Neutral rating on HDFC Bank, highlighting growth challenges. The bank's treasury head anticipates no RBI rate cuts until February. MSCI's index adjustment may boost foreign inflows, while the bank reports solid quarterly revenue and profit figures.HDFC Bank Hits Record High Amid Positive Sentiment - 04 Dec, 2024
HDFC Bank's stock reached a record high of ₹1,865, driven by strong market performance, MSCI rebalancing, and diminishing FII selling. Analysts predict further gains, potentially crossing ₹2,000 soon.HDFC Bank Shares Surge After Block Deal and Optimism - 03 Dec, 2024
HDFC Bank shares rose 2% after a significant block deal, reaching a record high of ₹1,837.40. The CEO expressed optimism about future growth and merger synergies.
Insights on HDFC Bank Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTFII Holding Up
Foreign Institutions have increased holdings from 40.79% to 41.54% in Sep 2024 quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, 1.16L Cr → 1.21L Cr (in ₹), with an average increase of 3.7% per quarter
- POSITIVE IMPACT
Price Rise
In the last 3 years, HDFCBANK stock has moved up by 23.1%
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, 16.47K Cr → 17.82K Cr (in ₹), with an average increase of 7.6% per quarter
NO EFFECTAgainst Peers
In the last 3 years, ICICI Bank Ltd has given 77.7% return, outperforming this stock by 54.6%
- NO EFFECT
Against Peers
In the last 1 year, ICICI Bank Ltd has given 30.0% return, outperforming this stock by 24.5%
NEGATIVE IMPACTMF Holding Down
Mutual Funds have decreased holdings from 21.48% to 21.22% in Sep 2024 quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 15.00% to 14.42% in Sep 2024 quarter
News
Aurobindo Pharma's Cancer Drug Approved by UK MHRA
CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, has received approval from the UKs Medicines and Healthcare Products Regulatory Agency (MHRA) to market its biosimilar version of bevacizumab, called Bevqolva. This drug is used to treat various types of cancer, including colorectal, lung, kidney, cervical, and ovarian cancers. The approval allows Bevqolva to be available in 25 mg/mL concentration for infusion, offered in two vial sizes: 4 mL (100 mg) and 16 mL (400 mg), both designed for vein infusion. Bevqolva is a biosimilar to the brand-name drug Avastin and is intended to provide a more affordable option for patients undergoing cancer treatment. Its approval marks an important step in expanding treatment choices for those battling several types of serious cancers.23 Dec, 2024 12:36 PMAurobindo Pharma Gains 2% After UK Approval for Bevqolva
Aurobindo Pharma share rose after it announced that CuraTeQ Biologics s.r.o., a step-down subsidiary of Aurobindo Pharma Limited, has obtained marketing authorisation from UK's Medicines and Healthcare products Regulatory Agency (MHRA) for Bevqolva, its bevacizumab biosimilar version. Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials for infusion into veins, Aurobindo Pharma said in a statement. Bevacizumab is used in the treatment of multiple cancers including metastatic colorectal cancer, recurrent or metastatic non-squamous non-small cell lung cancer, advanced and/or metastatic renal cell carcinoma, cervical cancer and epithelial ovarian, fallopian tube and primary peritoneal cancer. The market capitalisation of Aurobindo Pharma is Rs 73,326.20 crore, according to BSE. The company falls under the BSE 200 category. The 52-week high of Aurobindo Pharma share is Rs 1,592.55, while its 52-week low is Rs 959.05.23 Dec, 2024 12:13 PMAurobindo Pharma Shares Gain as Arm Secures Approval for Cancer Drug
Shares of Aurobindo Pharma Ltd were trading in the green and 1.8% higher on 23 December after the companys step-down subsidiary, CuraTeQ Biologics s.r.o., announced securing marketing approval from the UKs Medicines and Healthcare Products Regulatory Agencys (MHRA) for Bevqolva, its bevacizumab biosimilar version. Bevqolva 25 mg/mL concentrate will be available in single-use vials containing 4 mL (100 mg) and 16 mL (400 mg) for intravenous infusion. Numerous cancers can be treated with bevacizumab, including advanced and/or metastatic renal cell carcinoma, metastatic colorectal cancer, recurrent or metastatic non-squamous non-small cell lung cancer, cervical cancer, epithelial ovarian, fallopian tube, and primary peritoneal cancer, and more. Last week, the United States Food and Drug Administration (USFDA) issued two observations following its inspection of the Unit-V API manufacturing facility at Apitoria Pharma, a wholly owned subsidiary of the company, situated in Pashamylaram Village, Telangana. The inspection took place between 9 December and 17 December 2024. Earlier this month, the Medicinal Products for Human Use (CHMP) committee of the European Medicines Agency (EMA) expressed a favourable opinion for the filgrastim biosimilar Zefylti (BP13), recommending that CuraTeQ Biologics, the companys subsidiary, be given a marketing license. Furthermore, Eugia Pharma Specialities, the companys wholly owned subsidiary, has received final approval from the USFDA to manufacture and market 200 mg Pazopanib Tablets, which are therapeutically and bioequivalent to Votrient Tablets, the reference listed drug (RLD) of Novartis Pharmaceuticals Corporation. The product is expected to launch in the fourth quarter of FY25.23 Dec, 2024 11:25 AMHDFC Bank Ltd Financials
Index Inclusions
HDFC Bank Ltd Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 0% | 0.00 | |
| Foreign Institutions | 41.54% | 1.84 | |
| Mutual Funds | 21.22% | ||
| Retail Investors | 14.42% | ||
| Others | 22.81% | 0.37 |
HDFC Bank Ltd Key Indicators
HDFC Bank Ltd Valuation
HDFC Bank Ltd in the last 5 years
Lowest (15.43x)
February 14, 2024
Industry (15.53x)
December 27, 2024
Today (19.76x)
December 27, 2024
Highest (33.49x)
September 23, 2019
HDFC Bank Ltd Earnings and Dividends
HDFC Bank Ltd Earnings Results
HDFC Bank Ltd’s net profit jumped 6.03% since last year same period to ₹17,825.91Cr in the Q2 2024-2025. On a quarterly growth basis, HDFC Bank Ltd has generated 8.2% jump in its net profits since last 3-months.
Read More about Earnings ResultsHDFC Bank Ltd Dividends April,2024
In the quarter ending March 2024, HDFC Bank Ltd has declared dividend of ₹19.50 - translating a dividend yield of 1.08%.
Read More about Dividends
HDFC Bank Ltd Technicals Summary
Bearish
Neutral
Bullish
HDFC Bank Ltd is currently in a Bullish trading position according to technical analysis indicators.
FAQs on HDFC Bank Ltd
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy HDFC Bank Ltd shares.
HDFC Bank Ltd (HDFCBANK) share price today is ₹1798.25
HDFC Bank Ltd is listed on NSE
HDFC Bank Ltd is listed on BSE
- Today’s highest price of HDFC Bank Ltd is ₹1805.95.
- Today’s lowest price of HDFC Bank Ltd is ₹1789.1.
PE Ratio of HDFC Bank Ltd is 19.76
PE ratio = HDFC Bank Ltd Market price per share / HDFC Bank Ltd Earnings per share
Today’s traded volume of HDFC Bank Ltd(HDFCBANK) is 36.30L.
Today’s market capitalisation of HDFC Bank Ltd(HDFCBANK) is ₹1369515.42Cr.
| HDFC Bank Ltd(HDFCBANK | Price |
|---|---|
52 Week High | ₹1880 |
52 Week Low | ₹1363.55 |
HDFC Bank Ltd(HDFCBANK) share price is ₹1798.25. It is down -4.35% from its 52 Week High price of ₹1880
HDFC Bank Ltd(HDFCBANK) share price is ₹1798.25. It is up 31.88% from its 52 Week Low price of ₹1363.55
| HDFC Bank Ltd(HDFCBANK | Returns |
|---|---|
1 Day Returns | 7.5% |
1 Month Returns | 0.28% |
3 Month Returns | 3.82% |
1 Year Returns | 5.45% |